3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
4
Neoplasm Metastasis
3
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Solid Tumors
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rare Tumour
1
Rare Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Genomic Instability
1
Interventions
Gemcitabine
58
Cisplatin
32
Oxaliplatin
28
Fluorouracil
21
lenvatinib
19
durvalumab
18
Capecitabine
17
Leucovorin
15
tislelizumab
10
pembrolizumab
10
apatinib
9
Floxuridine
8
Specimen Handling
7
Panitumumab
7
Magnetic Resonance Spectroscopy
7
Albumin-Bound Paclitaxel
7
sintilimab
6
pemigatinib
6
Radiotherapy
6
Irinotecan
6
Drug Therapy
6
Biopsy
6
tremelimumab
5
regorafenib
5
olaparib
5
camrelizumab
5
Taxes
5
S 1 (combination)
5
Nivolumab
5
Folfox protocol
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cholangiocarcinoma
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts